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Montpellier, CNRS, Montpellier, France, 4 Department of Biology, Université de Fribourg, Fribourg, Switzerland
Aβ metabolism plays a pivotal role in Alzheimer’s disease. Here, we used a yeast model
to monitor Aβ42 toxicity when entering the secretory pathway and demonstrate that
processing in, and exit from the endoplasmic reticulum (ER) is required to unleash the
full Aβ42 toxic potential. Consistent with previously reported data, our data suggests
that Aβ42 interacts with mitochondria, thereby enhancing formation of reactive oxygen
species and eventually leading to cell demise. We used our model to search for genes
that modulate this deleterious effect, either by reducing or enhancing Aβ42 toxicity,
based on screening of the yeast knockout collection. This revealed a reduced Aβ42
toxicity not only in strains hampered in ER-Golgi traffic and mitochondrial functioning
but also in strains lacking genes connected to the cell cycle and the DNA replication
stress response. On the other hand, increased Aβ42 toxicity was observed in strains
affected in the actin cytoskeleton organization, endocytosis and the formation of
multivesicular bodies, including key factors of the ESCRT machinery. Since the latter
was shown to be required for the repair of membrane lesions in mammalian systems,
we studied this aspect in more detail in our yeast model. Our data demonstrated that
Aβ42 heavily disturbed the plasma membrane integrity in a strain lacking the ESCRT-
III accessory factor Bro1, a phenotype that came along with a severe growth defect
and enhanced loading of lipid droplets. Thus, it appears that also in yeast ESCRT
is required for membrane repair, thereby counteracting one of the deleterious effects
induced by the expression of Aβ42. Combined, our studies once more validated the use
of yeast as a model to investigate fundamental mechanisms underlying the etiology of
neurodegenerative disorders.
Keywords: Aβ42, amyloid beta, Alzheimer’s disease, ESCRT, membrane repair, Saccharomyces cerevisiae, yeast
INTRODUCTION
Amyloid β1−42 (referred to as Aβ42) is an intensively investigated peptide involved in Alzheimer’s
disease (AD) but beyond its role as a possibly malignant factor, the physiological functions of
Aβ42 are still speculative. It has been shown that it has a role in activity dependent synaptic
vesicle release and there is evidence that it might act as an antimicrobial agent in the brain,
but besides that, not much is known about its physiological function (Pearson and Peers, 2006;
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Abramov et al., 2009; Kagan et al., 2012; Kumar et al., 2016).
Thus, although several efforts have been put in investigating
its role in AD, still most of its functions remain elusive.
In humans, the membrane bound amyloid precursor protein,
APP, is processed in two possible ways: it can enter the non-
amyloidogenic pathway or it might be cleaved by β- and
γ-secretases in the amyloidogenic pathway thus producing Aβ
peptides of lengths between 37 and 43 amino acids (LaFerla
et al., 2007). In AD, these peptides are then secreted and
form inert extracellular plaques, but monomers and especially
small oligomers are transported to several intracellular organelles
where they reveal their toxic potential. For instance, strong
evidence was found for that Aβ42 perturbs proper function
of mitochondria through blocking respiration at complex IV,
resulting in cells producing more reactive oxygen species (ROS)
and eventually apoptotic cell death (Wang et al., 2010; Ittner and
Gotz, 2011; Benilova et al., 2012; Jackrel et al., 2014; Alexandrov
et al., 2016; Vicente Miranda et al., 2016).
In the past decade, yeast was established as a model organism
for studying fundamental aspects related to neurodegenerative
disorders such as Huntington’s, Parkinson’s, or AD (Winderickx
et al., 2008; Franssens et al., 2010; Swinnen et al., 2011; Porzoor
and Macreadie, 2013; Jiang et al., 2016; Verduyckt et al., 2016;
Fruhmann et al., 2017). Since most of the overall cellular
architecture and most basic biochemical processes are conserved
between mammalian cells and yeast, and given the fact that
about 20–30 per cent of all human genes have orthologs in
Saccharomyces cerevisiae (Foury, 1997; Hamza et al., 2015; Liu
et al., 2017), it is obvious that certain disease mechanisms
can be studied in this easy to handle model organism. In
connection to AD and Aβ42, we and others reported that
expression of this peptide triggers toxicity in yeast when targeted
to the secretory pathway as to mimic its multi-compartment
trafficking observed in mammalian systems. This led to the
observation that Aβ42 expression in yeast alters endocytosis
of plasma membrane resident proteins (Treusch et al., 2011;
D’Angelo et al., 2013), induces ER-stress and the unfolded
protein response (Chen et al., 2017) and triggers mitochondrial
dysfunction (D’Angelo et al., 2013; Chen and Petranovic, 2015;
Chen et al., 2017). In the studies presented in this paper,
we used previously reported constructs (D’Angelo et al., 2013;
Vignaud et al., 2013) where the yeast mating type α-prepro
factor directs Aβ42 into the Golgi. Here, the α-prepro factor is
cleaved off, followed by transport of the peptide to the plasma
membrane. In addition, the constructs contain a C-terminal
linker-GFP tag in order to ensure stable expression and easy
localization of Aβ42 in the yeast cells. Besides the wild-type Aβ42
and the clinical arctic mutant, we also expressed two synthetic
mutants generated by random mutagenesis and previously shown
to be either more toxic (Aβ42G37C) to, or to be moderately
toxic (Aβ42L34T) compared to Aβ42wt (D’Angelo et al., 2013;
Vignaud et al., 2013). Using these constructs, we performed
genome-wide screenings as to identify Aβ42 toxicity modulators.
We confirm the previously reported Aβ42 toxicity phenotypes
and in addition demonstrate that Aβ42 introduces membrane
lesions that require the ESCRT system in order to become
repaired.
MATERIALS AND METHODS
Yeast Strains, Plasmids, and Media
We used the haploid Saccharomyces cerevisiae strain BY4741
MATa his311 leu210 met1510 ura310 and BY4742 MATα
his311 leu210 lys210 ura310 for all specified experiments.
All deletion strains were obtained from the commercial
EUROSCARF knock-out library (Y.K.O. collection). For a full list
of strains used in this study see Table 1.
The pYe plasmids with the galactose inducible, episomal
αAβ42-linker-GFP isoforms, the similar Aβ42-GFP construct
without the α-prepro sequence and the control constructs for
expressing of either GFP (ev-GFP) or a α-prepro-GFP fusion
(ev-αGFP) were described previously (Tong et al., 2001). The
p426-GAL vector (Addgene) was used as additional empty vector
(ev) control. For a full list of plasmids used in this study see
Table 2.
Standard yeast techniques were applied. We used minimal
medium containing Yeast Nitrogen Base (YNB) without
ammonium sulfate (FORMEDIUM). Supplements were
ammonium sulfate (5 g/L; VWR), histidine (100 mg/L; MP
Biomedicals), methionine (20 mg/L; Acros Organics), leucine
(30 mg/L; FORMEDIUM) and lysine (30 mg/L; FORMEDIUM).
Synthetic Drop-Out (SD) medium was used for microscopy
and contained YNB with ammonium sulfate and was depleted
for either uracil or uracil and leucine (FORMEDIUM). For
solid media, 1.5% Difco-agar (BD) was added. Pre-cultures
were grown on medium supplemented with 4% glucose and
gene expression was induced by washing the cells with medium
without sugar followed by transfer to medium supplemented
with 2% galactose.
Synthetic Genetic Array and Suppressor
screening
The synthetic genetic array (SGA) screening was essentially
performed as previously described in Tong et al. (2001).
The query strain (MATα can11::STEpr-HIS5sp lyp11 his311
leu210 met1510 ura310 LYS2) expressing αAβ42wt-linker-GFP
(further designated as αAβ42wt), the αAβ42G37C-linker-GFP
(designated αAβ42G37C) or the ev-αGFP was mated with the
non-essential deletion mutant array (MATa target_gene::kanMX4
his311 leu210 met1510 ura310) on SD plates lacking uracil.
Diploids were selected on SD medium lacking uracil but
containing G418 (geneticin). Next, sporulation was induced
by plating diploids onto sporulation medium containing
G418. Then, haploids were selected in two steps. First,
spores were plated onto YNB lacking arginine, lysine, and
histidine but containing canavanine and thialysine, which
ensures uptake of canavanine. This allowed growth of MATa
haploids only. In a second step, the selected haploids were
grown on YNB lacking uracil, arginine, lysine, and histidine
but containing canavanine, thialysine and G418 to select
for haploid knock-out mutants still carrying the αAβ42wt,
αAβ42G37C, or ev-αGFP plasmids. Growth analysis was
performed with the ScreenMill software (Dittmar et al.,
2010).
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TABLE 1 | Yeast strains used in this study.
Name Genotype Source
Query strain (SGA) MATα can11::STEpr-HIS5sp lyp11 his311 leu210 met1510 ura310 LYS2 Tong et al., 2001
Deletion mutant strains (SGA) MATa Target_gene::kanMX4 his311 leu210 met1510 ura310 Tong et al., 2001
BY4741 MATa his311 leu210 met1510 ura310 Openbiosystems
BY4742 MATα his311 leu210 lys210 ura310 Openbiosystems
JW 12 918 MATa his311 leu210 met1510 ura310 erv29::kanMX Y.K.O. collection
JW 23 168 MATα his311 leu210 lys210 ura310 hse11::kanMX Y.K.O. collection
JW 23 771 MATα his311 leu210 lys210 ura310 vps27::kanMX Y.K.O. collection
JW 20 178 MATα his311 leu210 lys210 ura310 srn2::kanMX Y.K.O. collection
JW 21 184 MATα his311 leu210 lys210 ura310 mvb12::kanMX Y.K.O. collection
JW 21 335 MATα his311 leu210 lys210 ura310 stp22::kanMX Y.K.O. collection
JW 22 115 MATα his311 leu210 lys210 ura310 vps28::kanMX Y.K.O. collection
JW 23 142 MATα his311 leu210 lys210 ura310 vps25::kanMX Y.K.O. collection
JW 21 849 MATα his311 leu210 lys210 ura310 vps36::kanMX Y.K.O. collection
JW 22 164 MATα his311 leu210 lys210 ura310 snf8::kanMX Y.K.O. collection
JW 20 891 MATα his311 leu210 lys210 ura310 doa4::kanMX Y.K.O. collection
JW 22 100 MATα his311 leu210 lys210 ura310 bro1::kanMX Y.K.O. collection
JW 22 220 MATα his311 leu210 lys210 ura310 vps4::kanMX Y.K.O. collection
JW 22 777 MATα his311 leu210 lys210 ura310 did2::kanMX Y.K.O. collection
JW 24 370 MATα his311 leu210 lys210 ura310 vps60::kanMX Y.K.O. collection
JW 21 424 MATα his311 leu210 lys210 ura310 vta1::kanMX Y.K.O. collection
JW 23 123 MATα his311 leu210 lys210 ura310 chm7::kanMX Y.K.O. collection
JW 20 444 MATα his311 leu210 lys210 ura310 ist1::kanMX Y.K.O. collection
JW 20 124 MATα his311 leu210 lys210 ura310 snf7::kanMX Y.K.O. collection
JW 21 479 MATα his311 leu210 lys210 ura310 vps24::kanMX Y.K.O. collection
JW 22 806 MATα his311 leu210 lys210 ura310 vps20::kanMX Y.K.O. collection
JW 11 560 MATα his311 leu210 lys210 ura310 did4::kanMX Y.K.O. collection
TABLE 2 | Plasmids used in this study.
Name Backbone Marker Insert Source
αAβ42wt pYe-GAL10 2U URA3 α-prepro-Aβ42wt-linker-
GFP
D’Angelo et al., 2013
αAβ42arc pYe-GAL10 2U URA3 α-prepro-Aβ42arc-
linker-GFP
D’Angelo et al., 2013
αAβ42G37C pYe-GAL10 2U URA3 α-prepro-Aβ42G37C-
linker-GFP
D’Angelo et al., 2013
αAβ42G37C-HDEL pYe-GAL10 2U URA3 α-prepro-Aβ42G37C-
linker-GFP-HDEL
Christophe Cullin
αAβ42L34T pYe-GAL10 2U URA3 α prepro-Aβ42L34T-
linker-GFP
D’Angelo et al., 2013
ev-αGFP pYe-GAL10 2U URA3 α-prepro-GFP D’Angelo et al., 2013
ev-GFP pYe-GAL10 2U URA3 GFP D’Angelo et al., 2013
Ev p426-GAL1 URA3 Mumberg et al., 1994
pHS12-mCherry pHS12-ADH1 LEU2 COX4 Addgene
pYX242-mCherry pYX242-TPI LEU2 Kar2(1−135)-mCherry-
HDEL
Swinnen et al., 2014
In a second so-called suppressor screening, the Euroscarf
collection of deletion strains was pooled transformed with
αAβ42G37C. Transformants were plated on minimal medium
lacking uracil. After incubation, transformants were selected that
grew similar as the isogenic wild-type carrying the empty vector
control, also when replica plated on SD medium supplemented
with casamino acids. Transformants were then used for bar-code
PCR sequencing as to identify their corresponding ORF
deletion.
Electron Microscopy
Electron microscopic analysis of yeast cells was done similar
as previously described (Lefebvre-Legendre et al., 2005). Briefly,
pellets of yeast cells were placed on the surface of a copper
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EM grid (400 mesh) coated with formvar. Grids were immersed
in liquid propane held at −180◦C by liquid nitrogen and then
transferred in a 4% osmium tetroxide solution in dry acetone
at −82◦C for 72 h. They were warmed progressively to RT, and
washed three times with dry acetone and stained with 1% uranyl
acetate. After washing in dry acetone, the grids were infiltrated
with araldite (Fluka). Ultra-thin sections were contrasted with
lead citrate and observed in an electron microscope (80 kV; 7650;
Hitachi) at the EM facility of the Bordeaux Imaging Center.
Growth Profile Analysis and Spot Assays
Cells were grown under non-inducing conditions in 96-well
plates shaking at 30◦C in a Multiskan GO or Multiskan
FC microplate spectrophotometer (Thermo Scientific) to an
OD595 nm or OD600 nm, respectively, of 0.5 to 0.9. Cells were
washed with minimal medium containing galactose and diluted
to an OD595 nm or OD600 nm, respectively, of 0.5 after which
growth was monitored every 2 h by OD measurement. Four
different transformants were taken per experiment and at least
three independent experiments were performed. Growth curves
were analyzed with GraphPad Prism v7.03, error bars represent
standard deviations.
For spot assays, serial dilutions of precultures were spotted
on solid medium containing either glucose or galactose and cells
were grown at 30◦C. The plates were scanned at days 3 to 6.
Cytometry and Fluorescence Microscopy
To monitor plasma membrane disruption with propidium iodide
(PI) staining and the formation of ROS by dihydroethidium
(DHE) staining, cells were grown in SD medium lacking
uracil and containing 4% glucose. Once in exponential phase,
the cells were washed with and re-suspended in SD medium
without uracil but containing 2% galactose as to induce
expression of αAβ42-linker-GFP and control constructs. Flow
cytometric analysis was performed on at least four independent
transformants with a Guava easyCyte 8HT benchtop flow
cytometer (Millipore) after staining with 5 µM PI for 30 min at
30◦C and subsequent washing. Data were analyzed with FlowJo
v10 and GraphPad Prism 7.03 software packages. Gates were
set in FlowJo v10 with single stained ev-αGFP samples. Further
statistical analysis was done in GraphPad Prism v7.03. Error
bars represent standard deviations and asterisks the significance
calculated with an ordinary Two-way ANOVA.
For the FM4-64/CMAC (Thermo Fisher) and Nile Red (Acros)
stainings, the cells were grown as described above. After pre-
incubating the cells with CAMAC at 30◦C for 30 min, FM4-64
stainings were performed as described before (Zabrocki et al.,
2005). For the Nile Red staining, the cells were fixed with
formaldehyde (4% final concentration) and stained with 2% Nile
Red (60 µg/mL stock) for 30 min with shaking at 30◦C. Then,
the cells were washed twice with PBS and either stored at 4◦C or
taken immediately for fluorescence microscopy.
For epifluorescence pictures, cells were pre-grown in selective
glucose (4%) containing SD medium to exponential phase.
After transfer to SD medium containing 2% galactose to induce
expression of αAβ42-linker-GFP, the cells were grown at 30◦C
and pictures were taken after different time intervals using a
Leica DM4000B or a DMi8 microscope. For Hoechst stainings,
the cells were incubated with 20 nM Hoechst 33342 (Sigma-
Aldrich) for 10 min. Pictures were deconvolved with Huygens
Essential software (v18.04.0p4 64, Scientific Volume Imaging
B.V.) and further processed with the standard FIJI software
package (v1.51n) (Schindelin et al., 2012).
Immunological Techniques
Cultures were grown to exponential phase in 4% glucose
containing SD medium, transferred to 2% galactose containing
medium and grown overnight. Then, three OD units were
harvested by centrifugation and protein extracts were prepared
by using an alkaline lysis method. The cells were permeabilized
with 0.185 M NaOH plus 2% β-mercaptoethanol. After 10 min
incubation on ice, trichloroacetic acid (TCA) was added to a final
concentration of 5%, followed by an additional 10 min incubation
step on ice. Precipitates were collected by centrifugation for 5 min
at 13000 g and pellets were resuspended in 50 µL of sample
buffer (4% sodium dodecyl sulfate, 0.1 M Tris-HCl pH 6.8,
4 mM EDTA, 20% glycerol, 2% β-mercaptoethanol, and 0.02%
bromophenol blue) plus 25 µL of 1 M Tris-Base. Samples were
separated by standard SDS-PAGE on 12% polyacrylamide gels
and further analyzed using standard Western blotting techniques.
An anti-GFP primary antibody (Sigma-Aldrich) and anti-Mouse
(GAM)-HRP conjugated secondary antibody (Biorad) were used.
The ECL method (SuperSignal West Pico or Femto, Thermo
Scientific) was used for detection and visualization of the blots
was performed with a UVP Biospectrum R© Multispectral Imaging
System.
RESULTS
αAβ42-Linker-GFP Is Toxic in an AD Yeast
Model
To date, the exact molecular basis of how Aβ42 impacts cell
functions remains largely elusive. To address this question,
we used a yeast model transformed with plasmids carrying
the galactose-inducible GAL10 promoter to control expression
of wild-type or mutant Aβ42 that is N-terminally fused to
the α-prepro sequence and C-terminally to a linker and GFP
(in this paper referred to as αAβ42; Figure 1A) (D’Angelo
et al., 2013; Vignaud et al., 2013). Besides the wild-type
αAβ42 (αAβ42wt), we additionally expressed the clinical E22G
arctic mutant (αAβ42arc) that is associated to a familial
form of AD as well as the previously described synthetic
mutants αAβ42G37C and αAβ42L34T (Figure 1A) (D’Angelo
et al., 2013; Vignaud et al., 2013). We used three control
vectors, i.e., an empty vector allowing for the expression of
an α-prepro fused GFP (ev-αGFP), GFP alone (ev-GFP) or
an empty vector just carrying the galactose promotor (ev).
To disperse concerns about the processing efficacy of the
α-prepro factor in the Golgi system, we tested both the BY4741
MATa and BY4742 MATα strains with all control vectors and
the aforementioned wild-type and mutant αAβ42-linker-GFP
constructs (Figures 1B–D and Supplementary Figure S1). Albeit
the strains transformed with the ev-αGFP control grew somewhat
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FIGURE 1 | Toxicity profiles of wild-type or mutant αAβ42 in the haploid Saccharomyces cerevisiae strains BY4741. (A) Schematic representation of the
α-prepro-Aβ42-linker-GFP construct with indication of the mutants used in this study. (B) Spot assays under inducing (galactose) and repressing (glucose) conditions
and (C) growth profiles under inducing conditions of the BY4741 wild-type strain transformed with constructs allowing for expression of αAβ42wt, αAβ42arc,
αAβ42G37C, αAβ42L34T, Aβ42wt and control vectors (ev-αGFP, ev-GFP, ev) as indicated. Error bars in the growth profiles represent the standard deviation of at least
four independent transformants. (D) Fluorescence microscopy pictures show localization of α-prepro fused Aβ42 mutants to the ER 6 and 24 h after induction on
galactose-containing medium. 24 h after induction of gene expression the toxic αAβ42 isoforms show a more “patchy” pattern while the non-toxic αAβ42L34T still
localizes at the ER. The Aβ42wt construct lacking the α-prepro sequence is seen in the cytoplasm. The scale bar represents 2 µm. (E) Growth profiles of the BY4741
wild-type strain transformed with an empty vector (ev) or constructs allowing for expression of αAβ42wt and Aβ42wt.
slower than those transformed with ev-GFP or ev (Figures 1B,C
and Supplementary Figure S1A), both spot assays and growth
analysis in liquid medium confirmed that wild-type or mutant
αAβ42 instigated a significantly higher level of toxicity that was
similar in the BY4741 and the BY4742 strains (Figures 1B,C and
Supplementary Figure S1). The synthetic αAβ42G37C mutant
was the most toxic followed by αAβ42wt and αAβ42arc. The
synthetic αAβ42L34T mutant, on the other hand, did not yield
a toxic phenotype and these transformants grew similar as those
expressing ev-αGFP, thereby confirming previously reported data
(Vignaud et al., 2013).
Fluorescence microscopy showed that all αAβ42 constructs
clearly stained the perinuclear ER and to a lesser extent the
cortical ER and that particularly the cells expressing the toxic
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αAβ42 forms often displayed ER-associated foci and filamentous
structures (Figure 1D). These were previously believed to be
vesicles (D’Angelo et al., 2013), but recent studies suggests that
these may as well-represent ER-aggregates or clustering of ER
membranes, both indicative for ER stress (Varadarajan et al.,
2012, 2013; Vevea et al., 2015). In contrast, when the Aβ42wt was
expressed from a construct that lacks the α-prepro sequence, the
GFP fusion was mainly found to be distributed in the cytoplasm
though some cells presented foci after prolonged induction
(Figure 1D). Despite of these foci, the expression of the Aβ42wt
construct without the α-prepro sequence only triggered a small
growth retardation (Figures 1B,E). This nicely demonstrates that
the processing in the ER/Golgi system is required to unleash the
full toxic capacity of αAβ42.
Retention of αAβ42 in the ER Diminishes
Its Toxicity
Previously, we reported that the processing of the αAβ42-linker-
GFP fusion constructs in the ER/Golgi system yields three
distinct isoforms when performing Western blot analysis, i.e.,
the α-prepro precursor (41 kDa), the glycosylated precursor
(50 kDa), and the matured Aβ42-linker-GFP form (34 kDa)
(D’Angelo et al., 2013; Vignaud et al., 2013). Given that the
latter is shuttled into the secretory pathway, we wondered if
retention of the αAβ42-linker-GFP fusion in the endoplasmic
reticulum (ER) would affect its toxic capacity. To this end,
we introduced a HDEL retention signal at the C-terminal
end of the construct. The yeast HDEL sequence is equivalent
to the mammalian KDEL retention signal that shuttles the
KDEL containing proteins back to the ER lumen (Dean and
Pelham, 1990; Lewis and Pelham, 1990; Ruan et al., 2017).
Consistently, microscopic analysis demonstrated that while both
αAβ42G37C and αAβ42G37C-HDEL are equally present at the
perinuclear ER, the latter accumulated more in the peripheral
cortical ER (Figure 2A). Also, Western blot analysis showed
that in case of expression of αAβ42G37C-HDEL, both the non-
processed αAβ42G37C precursor as well as the glycosylated
version accumulated, while the fully processed Aβ42G37C was
significantly reduced (Figure 2B). Next, a growth analysis was
performed. This revealed that the strain expressing αAβ42G37C-
HDEL construct grew much better than that with αAβ42G37C,
thereby displaying a level of toxicity comparable to a strain with
the αAβ42arc mutant (Figure 2C).
In order to confirm these results with a different approach,
we expressed αAβ42wt, αAβ42arc, as well as the super-toxic
αAβ42G37C mutant in a BY4741 strain deleted for ERV29, which
encodes a transmembrane factor involved in COP-II dependent
vesicle formation and in trafficking of the α-prepro factor from
the ER to the Golgi apparatus (Belden and Barlowe, 2001). Upon
deletion of ERV29, αAβ42 gets stuck in the ER and cannot transit
to the Golgi. Strikingly, cytotoxicity of all tested mutants was
indeed significantly diminished in this erv291 strain and even the
super-toxic αAβ42G37C mutant almost completely lost its toxic
power (Figures 2D,E). Thus, the data above confirm that αAβ42
needs to be fully processed and exit the ER in order to gain its full
toxic potential.
αAβ42 Affects Mitochondrial Functioning
Since αAβ42 confers toxicity by entering the secretory pathway,
we wanted to know more about the targets and processes being
affected. Therefore, we first focused on mitochondria given
that previous studies have associated Aβ42 to mitochondrial
dysfunction in yeast (Chen and Petranovic, 2015; Chen et al.,
2017; Hu et al., 2018). To this end, we co-expressed αAβ42wt,
αAβ42arc, αAβ42G37C, αAβ42L34T or the ev-αGFP together with
a mCherry labeled mitochondrial marker Cox4 in wild-type cells.
As illustrated in Figure 3A, this suggests a toxicity dependent
co-localization since αAβ42wt and even more αAβ42G37C seem
to partially co-localize with mitochondria. We then performed
a DHE staining to estimate the ROS levels as marker for
mitochondrial dysfunction and a PI staining to monitor the
amount of cells with disrupted plasma membranes as marker for
cell demise (Figures 3B,C and Supplementary Figure S2). As
expected, and consistent with previously reported data (Chen and
Petranovic, 2015; Chen et al., 2017), also these aspects correlated
to the observed αAβ42 instigated toxicity. Although our data
on co-localization suggest that αAβ42 may directly interfere
with mitochondrial functioning, we cannot exclude that these
effects on mitochondrial function or morphology are indirect, for
instance due alterations in ER-mitochondrial communication via
ERMES contact sites.
Identification of Additional Processes
Underlying αAβ42 Toxicity
To decipher which additional processes sustain the αAβ42
toxicity, we performed two unbiased genetic screens. In a first
screening setup, we aimed to identify alleviators of Aβ42G37C
toxicity. Therefore, we transformed a pooled Euroscarf knock-
out (KO) library with the αAβ42G37C-linker-GFP construct and
looked for transformants that grew similar as the empty vector
control. Out of 90,000 transformants obtained when plated on
repressive glucose containing medium, only 465 were able to
form visible colonies after 72 h on galactose-containing medium
where the expression of the super-toxic Aβ42 mutant is induced.
Each colony was then plated on SD medium supplemented with
casamino acids to manually confirm the suppressive effect on
αAβ42 toxicity. Of the 465 initial clones, 268 were still able to
grow. Finally, we characterized each KO strain by sequencing
the PCR amplicon of its bar-code region. This led us to identify
113 different KO strains. In the second screening setup, we
performed an unbiased SGA analysis with the full gene knock-
out library using either αAβ42wt, the super-toxic αAβ42G37C
mutant and the ev-GFP control. The additional use of the empty
vector control and αAβ42wt, which displays a more moderate
toxicity phenotype, allowed for more complete results since not
only suppressors but also toxicity aggravators could be scored.
With this SGA screen, we identified 87 additional KO strains that
modulated αAβ42 toxicity, one of which contains a deletion in
the overlapping genes INP52/RRT16. Finally, the 200 KO strains
that were identified by either one of the screening procedures
(Table 3 and Supplementary Table S1) were also transformed
individually with a construct allowing for the expression of
αAβ42arc, which has an intermediate toxicity similar to that
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FIGURE 2 | Retention of αAβ42 in the ER and the consequence for toxicity. (A) Fluorescence microscopy pictures showing αAβ42G37C and αAβ42G37C-HDEL
localization at the perinuclear and cortical ER. Scale bar represents 2 µm. (B) Western blot analysis of total protein extracts obtained from cells expressing either
αAβ42G37C and αAβ42G37C-HDEL. The different processing isoforms are indicated, i.e., αAβ∗42 indicates glycosylated αAβ42, αAβ42 indicates un-glycosylated
αAβ42 and Aβ42 indicates fully processed form where the α-prepro sequence is cleaved off. Spot assays under inductive (galactose) and repressive (glucose)
conditions of wild-type (C) or erv291 (D) cells transformed with the empty vector (ev) or constructs allowing for expression of αAβ42wt, αAβ42arc, αAβ42G37C, or
αAβ42G37C-HDEL as indicated. (E) Growth profiles of erv291 transformed with the empty vector (ev) or constructs allowing for expression of αAβ42wt, αAβ42arc, or
αAβ42G37C when grown on galactose-containing medium.
of αAβ42wt and thus is again ideal to provide confirmation of
both aggravators and suppressors of toxicity (D’Angelo et al.,
2013). This provided an independent confirmation that all the
KO strains selected in one of the two genetic screens are indeed
involved in modulating αAβ42arc toxicity. For each of the KO
strains, the cell density under galactose inducing conditions was
monitored allowing to rank KO strains from 0 to 5 depending
on the growth capacity in comparison to the wild-type strain
transformed αAβ42arc. For 29 KO strains, growth was improved
strongly (scored as 5), for 18 KO strains growth was clearly
improved (scored as 4) and for 129 KO strains growth was only
slightly better (scored as 3). On the other hand, we also identified
2 KO strains in which αAβ42arc toxicity was strongly enhanced
(scored as “0”) and 17 KO strains that enhanced αAβ42arc toxicity
moderately (scored as 1) or weakly (scored as 2) (Table 3 and
Supplementary Table S1). Next, a gene ontology (GO) analysis
using the SGD Gene Ontology Slim Mapper1 allowed to sort
the KO strains into functional categories depending on the gene
deleted (Table 3). These included, amongst others, cytoskeleton
organization and endocytosis, protein sorting and trafficking,
protein ubiquitination, plasma membrane transport, cell cycle,
translation, and transcription.
Interestingly, among the many KO strains that alleviated
αAβ42arc toxicity we found not only the strain deleted for
ERV29, which is in line with the data described above, but also
strains lacking other genes that impact on ER/Golgi functioning
1https://www.yeastgenome.org/cgi-bin/GO/goSlimMapper.pl
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FIGURE 3 | αAβ42 induces mitochondrial dysfunction and cell demise. (A) Fluorescence microscopy pictures suggesting partial co-localization of toxic αAβ42 but not
of the non-toxic αAβ42L34T nor of the αGFP control (green) with mitochondria (red) in wild-type cells. Hoechst staining (blue) shows mitochondrial as well as nuclear
DNA. The white arrowheads indicate sites of co-localization between αAβ42 and mitochondria. Two single cells shown per strain. Scale bars represent 2 µm.
Percentage of wild-type yeast cells expressing wild-type or mutant αAβ42 and a control stained with DHE as a marker for ROS-formation (B) or PI as a marker for
plasma membrane integrity (C). ∗P ≤ 0.05; ∗∗P ≤ 0.01; ∗∗∗∗P ≤ 0.0001; nsP > 0.05.
and traffic, such as the SPC2 encoded subunit of the peptidase
complex, which cleaves the signal sequence from proteins
targeted to the ER, EMP24, which encodes a component of
the p24 complex that mediates ER-to-Golgi transport of GPI
anchored proteins, or ARF2 and YPT31, which both encode
GTPases required for intra-Golgi traffic. Also found were several
strains lacking genes encoding mitochondrial functions and
this included AIF1 that codes for the mitochondrial cell death
effector, indicative that αAβ42 actively induces programmed cell
death pathways. Furthermore, the fact that we retrieved the
KO strains for ATG1, ATG2, and ATG20 suggests that αAβ42
may overstimulate the autophagy and the cytoplasm-to-vacuole
targeting pathways (Kim and Klionsky, 2000; Nice et al., 2002).
Finally, it was recently shown by transcriptome analysis that Aβ42
impacts on lipid metabolism with INO1 being most significantly
upregulated (Chen et al., 2017). We found the KO strain lacking
ITC1 to reduce αAβ42 toxicity. ITC1 encodes a subunit of ATP-
dependent Isw2p-Itc1p chromatin remodeling complex that is
required for repression of INO1. In addition, also KO strains
lacking genes involved sphingolipid and ceramide metabolism
were retrieved, i.e., FAA1, SUR1, YDC1. Overall, these data
confirm that the noxious effect of αAβ42 is associated to changes
in lipid metabolism.
The KO strains that aggravated αAβ42 toxicity were often
missing functions associated to maintenance and organization
of the actin cytoskeleton, endocytosis and the multivesicular
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TABLE 3 | αAβ42 toxicity modifiers.
GO term Enhancers Suppressors
Biological process unknown FMP41 (2), MTC3 (2), YBR113W (2), YHL005C
(2), YJL169W (2)
GL081W (3), ICY1 (3), IRC10 (3), MRX11 (3), NBA1 (3), NRP1 (3),
PHM7 (3), PRM9 (3), RRT16 (3), TDA8 (3), URN1 (3), YBR209W (3),
YBR284W (3), YCR085W (3), YCR099C (3), YDR042C (3),
YER067C-A (3), YER186C (3), YGL101W (3), YGR259C (3),
YIL014C-A (3), YKL066W (3), YL043W (3), YLR042C (3), YLR279W
(3), YLR283W (3), YML096W (3), YML119W (3), YMR102C (3),
YMR153C-A (3), YMR160W (3), YMR178W (3), YMR244W (3),
YMR316C-A (3), YMR317W (3), YNL146W (3), YOR263C (3),
YPL257W (3), YGL109W (4), YJL007C (4), YMR114C (4), YNL338W
(4), YNR071C (4), YGL072C (5), YLR149C (5), YML084W (5),
YMR103C (5), YOR296W (5), YPL247C (5)
Cell cycle END3 (2), RIM8 (2), CCR4 (2) CLN1 (3), DIA2 (3), FYV5 (3), GAS2 (3), MAM1 (3), NFI1 (3), PCL1
(3), PEA2 (3), REC114 (3), PRM3 (3), SMK1 (3), SRC1 (3), SSO2 (3),
SSP1 (3), TEC1 (3), TEP1 (3), TOF1 (3), YOR338W (3), BDF2 (4),
ITC1 (4), REI1 (4), XRN1 (4), ADA2 (5), CLB3 (5), CSM4 (5), STE24
(5), YHP1 (5), ZDS1 (5)
Cell morphology END3 (2) GAS2 (3), GPD2 (3), PEA2 (3), SMK1 (3), SSP1 (3), TEP1 (3), REI1
(4)
Cytoskeleton SAC6 (0), BEM2 (2), END3 (2), RVS167 (0),
SLA1 (2) TDA2 (2)
ABP1 (3), PCL1 (3), PEA2 (3), SLM2 (3), WHI2 (3), CLB3 (5), PFD1
(5)
DNA CCR4 (2), SLX8 (2) ADA2 (5), CSM4 (5), DIA2 (3), HCS1 (3), RAD34 (3), REC114 (3),
RPB9 (3), SLX5 (3), TEC1 (3), TOF1 (3)
Mitochondria MTC3 (2), FMP41 (2), RTG1 (2), SAM37 (2) HEM25 (3), MRX5 (3), AIM25 (3), YLR283W (3), GUF1 (3), AIF1 (3),
ODC1 (3), MDL2 (3), YME1 (3), SUE1 (3), PKP1 (4), FMP25 (4),
RSM25 (5), FMP30 (5)
Metabolism TDA9 (2) ALD2 (3), ALD3 (3), CPA1 (3), FAA1 (3), FAA3 (3), FAU1 (3), GPD2 (3),
LEU4 (3), NMA1 (3), SNO2 (3), SUR1 (3), YDC1 (3), IGD1 (4), FMP30
(5), HIS1 (5), PSK2 (5), SPE2 (5)
Organelle organization SAM37 (2), RIM8 (2) ABP1 (3), AIM25 (3), ATG1 (3), ATG2 (3), ATG20 (3), DID2 (3), DJP1
(3), IWR1 (3), MAM1 (3), NGR1 (3), PEA2 (3), PEX6 (3), PRM3 (3),
REC114 (3), SPC2 (3), SRC1 (3), SSO2 (3)TOF1 (3), VPS68 (3),
WHI2 (3), YME1 (3), BDF2 (4), FMP25 (4), ADA2 (5), CLB3 (5),
CSM4 (5) SCD6 (5)
Other BEM2 (2), END3 (2), RIM8 (2), RTG1 (2) ADH6 (3), APE2 (3), ARF2 (3), DIA2 (3), FDO1 (3), FYV5 (3), IGO2 (3),
ODC1 (3), OXP1 (3), PEX6 (3), PML39 (3), SLM2 (3), GAS2 (3),
SMK1 (3), SSO2 (3), SSP1 (3), SUE1 (3), TEC1 (3), TEP1 (3), TVP18
(3), YML082W (3), YOR338W (3), ECM4 (4), PDE2 (4), YGR111W (4)
Protein modification SNF7 (1), HPM1 (2), PKR1 (2), RIM8 (2),
SAM37 (2), SLA1 (2), SLX8 (2), UMP1 (2),
VPS24 (2)
ABP1 (3), ATG1 (3), CLN1 (3), CPS1 (3), CUL3 (3), CUR1 (3), DIA2
(3), NFI1 (3), HRT3 (3), MAM1 (3), PCL1 (3), SLX5 (3), SMK1 (3),
SPC2 (3), SSP1 (3), TUL1 (3), YME1 (3), FMP25 (4), PKP1 (4), XRN1
(4), ADA2 (5), CLB3 (5), PFD1 (5), PSK2 (5), STE24 (5)
RNA CCR4 (2) DEG1 (3), HIT1 (4), NGL2 (3), RPB4 (3), RPS8A (3), XRN1 (4), CBC2
(5), MSL1 (5), SNT309 (5), TSR3 (5)
Stress response SNF7 (1), PKR1 (2), PMP3 (2), RTG1 (2),
RVS167 (0), SLX8 (2), UMP1 (2)
AIF1 (3), AIM25 (3), CUR1 (3), FYV5 (3), HYR1 (3), MDL2 (3), MIG1
(3), PEA2 (3), RAD34 (3), RPB4 (3), RPB9 (3), SLX5 (3), SMF3 (3),
TOF1 (3), YCR102C (3), ITC1 (4), TRK1 (5), WHI2 (3), ADA2 (5),
YAR1 (5)
Transcription CCR4 (2), RTG1 (2), TDA9 (2) CAF120 (3), FUI1 (3), GAT2 (3), ITC1 (4), MIG1 (3), RPB4 (3), RPB9
(3), TEC1 (3), YOR338W (3), FZF1 (4), STP1 (4), XRN1 (4), ADA2 (5),
MBF1 (5), PFD1 (5), YHP1 (5)
Translation RPS7A (2) GUF1 (3), NGR1 (3), RPB4 (3), RPS7B (3), RPS8A (3), HIT1 (4), REI1
(4), PSK2 (5), RPL2B (5), RSM25 (5), SCD6 (5), TSR3 (5), YAR1 (5)
Transport (not vesicular) SNF7 (1), PMP3 (2), SAM37 (2), VPS24 (2) ATO3 (3), DJP1 (3), FAA1 (3), FUI1 (3), GFD1 (5), HEM25 (3), IWR1
(3), MDL2 (3), MSN5 (3), NRT1 (3), PEX6 (3), PUT4 (3), RPB4 (3),
SMF3 (3), YME1 (3), YOL163W (3), FZF1 (4), REI1 (4),YAR1 (5),
ZDS1 (5)
Vesicles/trafficking RVS167 (0), SNF7 (1), END3 (2), RIM8 (2),
SLA1 (2), VPS24 (2)
ATG20 (3), DID2 (3), EMP24 (3), PRM3 (3), SLM2 (3), SSO2 (3),
VPS68 (3), WHI2 (3), YPT31 (3), SLM6 (4), ERV29 (5)
Enhancers and suppressors of the αAβ42 instigated toxicity are shown. Genes are sorted according to the Gene Ontology (GO) terms. Category “Mitochondria” was
manually added according to GO terms list. Genes that occur in more than 1 GO-term category are in bold. The numbers between brackets refer to the growth scores
ranging from 0 (worst growth) to 5 (best growth). See main text for details.
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FIGURE 4 | Interference of αAβ42 with endocytosis. (A) Growth profiles of wild-type cells and rvs1671 or sac61 cells transformed with the empty vector (ev) or a
construct allowing for expression of αAβ42wt when grown on galactose-containing medium. (B) Fluorescence microscopy pictures of strains expressing the toxic
αAβ42wt and αAβ42G37C or the non-toxic αAβ42L34T stained with the endocytosis tracker FM4-64 (red) and CMAC (blue), a dye to stain the vacuolar lumen. The
scale bar represents 2 µm.
body (MVB) pathway. The two strains with the strongest
enhanced toxicity were those carrying a deletion of SAC6 or
RVS167. Sac6 is an actin-bundling protein that is required for
endocytosis (Penalver et al., 1997; Gheorghe et al., 2008). Rvs167
is a homolog of mammalian amphiphysin that interacts with
actin as well and that functions in the internalization step of
endocytosis (Lombardi and Riezman, 2001). As illustrated for
the expression of αAβ42wt, we indeed observed a similar severe
growth phenotype in both the sac61 and rvs1671 mutants as
compared to the isogenic wild-type strain (Figure 4A). To further
confirm the link between endocytosis and αAβ42 toxicity, we also
monitored the uptake of the endocytosis tracker FM4-64 by wild-
type cells expressing either the toxic αAβ42wt and αAβ42G37C
and non-toxic αAβ42L34T isoforms after 4 h induction on
galactose-containing medium. As shown, FM4-64 already stained
the vacuolar membrane within 30 min in cells expressing the
non-toxic construct while no, or only a minimal staining of the
vacuolar membrane was observed in cells expressing the toxic
αAβ42 species, even not after 60 min of incubation (Figure 4B).
This demonstrates that the latter have a direct impact on the
endocytic process.
αAβ42 Enhances the Occurrence of
Plasma Membrane Lesions and
Formation of Lipid Droplets
Closely connected to endocytosis, we noticed that our screening
retrieved some ESCRT components, which function in the MVB
pathway that is required for the turnover of plasma membrane
proteins and lipids. The first step in MVB formation is the
binding of ESCRT-0 (Hse1 and Vps27) and ESCRT-I (involving
Vps28, Mvb12, Srn2, and Stp22) to ubiquitinated MVB cargoes.
Next, the ESCRT-II complex (involving Vps25, Vps36, and
Snf8) mediates the recruitment of ESCRT-III accessory factors
(Bro1 and Doa4), which in turn loads general ESCRT-III factors
(Vps20, Snf7, Did4, Chm7, Ist1, and Vps24) to direct the
continued sorting of cargoes into invaginating vesicles during
MVB formation. ESCRT-III dissociation factors (Vps4, Vps60,
Did2, and Vta1) mediate the release and recycling of all involved
factors (Hurley, 2010; Babst, 2011). All the 21 corresponding
genes are not essential and could therefore be tested for their
implications in αAβ42 toxicity. After transformation of the
corresponding KO strains with either αAβ42wt, αAβ42G37C
or the ev-αGFP control construct, we evaluated the impact
of the deletions on αAβ42 toxicity through spot assays. This
revealed that for several components of the MVB pathway their
deletion significantly aggravated αAβ42 toxicity. This included
the ESCRTIII components Did4, the ESCRTIII accessory
components Bro1 and Doa4 as well as the ESCRTIII dissociation
mediator Vps4 (Supplementary Figures S3, S4). Recent studies
in mammalian cells have demonstrated that besides its role in
the MVB pathway, ESCRT plays key roles in a variety of other
processes, including membrane lesion repair (Jimenez et al.,
2014; Sundquist and Ullman, 2015; Campsteijn et al., 2016;
Denais et al., 2016; Raab et al., 2016). It is well-established
that Aβ42 can introduce membrane lesions and different non-
excluding mechanisms were proposed, including membrane lipid
interaction, alterations in membrane fluidity, pore formation,
or lipid oxidation (Eckert et al., 2000; Muller et al., 2001;
Ambroggio et al., 2005; Rauk, 2008; Axelsen et al., 2011; Viola
and Klein, 2015). We speculated that αAβ42 would also trigger
membrane lesions in our yeast system. To test this, we analyzed
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FIGURE 5 | The role of Bro1 for membrane lesion repair. (A) Growth profile on galactose-containing medium of a strain deleted for the ESCRT-III accessory factor
BRO1 transformed with an empty vector (ev-αGFP) or constructs allowing for expression of αAβ42wt or αAβ42G37C. Cryo-EM pictures (B) and fluorescence
microscopy pictures (C) of wild-type and bro11 cells transformed with an empty vector (ev) or expressing αAβ42wt and grown for 6 h on galactose-containing
medium. The indents in panel (B) zoom in on the plasma membrane and cell wall. The black arrowhead in (B) indicates a lipid droplet. Scale bars for cryo-EM
pictures represent 200 nm. (D) BY4742 wild-type and a bro11 strains transformed with a plasmids carrying αAβ42wt and additionally a plasmid allowing the
expression of Kar2(1−135)-mCherry-HDEL (ERCherry), a marker for the ER. DNA was stained with Hoechst. Cells were grown in medium allowing for gene
expression for 6 h prior to microscopy. Scale bars for fluorescence pictures represent 2 µm. (E) PI staining of cells deleted for BRO1 transformed with constructs
allowing for expression of αAβ42wt, αAβ42L34T, αAβ42G37C, or αGFP after 4 or 24 h growth on galactose-containing medium. Error bars represent standard
deviations of at least four independent transformants.
the plasma membrane integrity of wild-type and bro11 cells
by cryo-EM. We chose the bro11 strain because here αAβ42wt
and αAβ42G37C was almost lethal (Figure 5A) and because
Bro1 is the yeast ortholog of human Alix, a proposed biomarker
for AD (Sun et al., 2015). Consistent with our hypothesis, the
cryo-EM study showed that the plasma membrane of bro11
cells expressing αAβ42wt seemed heavily corrugated while the
bro11 cells transformed with empty vector displayed a more
modest phenotype. In the wild-type strain, the plasma membrane
remained ostensibly smooth even upon expression of αAβ42wt
(Figure 5B). However, although we did not quantify, the
observed membrane corrugating effects of specifically the bro11
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strain expressing αAβ42wt are strikingly obvious. Moreover,
when compared to the wild-type cells, the ER morphology in
the bro11 mutant was completely different and appeared to be
deteriorated. Indeed, only a minimal perinuclear and cortical
ER was detected and the cells displayed the αAβ42-linker-GFP
fusion mostly in filamentous structures and foci (Figures 5C,D).
Thus, expression of αAβ42wt seems to dramatically affect all
membranous structures evidencing that Bro1, and by extension
the ESCRT system, is absolutely required for the repair of
membrane lesions induced by αAβ42. In line with this essential
requirement of ESCRT, we observed that while still seeing a
tendency of increased PI uptake after 4 h induction for those
bro11 cells expressing toxic αAβ42, a maximal PI uptake in all
bro11 transformants is seen after 24 h, even for those strains
expressing the non-toxic αAβ42L34T mutant or the ev-αGFP
control (Figure 5E).
The cryo-EM study also pointed to the formation of cortical
vesicle-like structures, which we believe may correspond to lipid
droplets. Since previous studies have shown that the formation
of lipid droplets denotes an adaptive response to a chronic
lipid imbalance (Vevea et al., 2015; Garcia et al., 2018), which
is likely to occur in bro11 strain because of hampered MVB
formation and lipid turnover, we decided to perform a Nile Red
staining to visualize the droplets. While during the first hours
of induction on galactose-containing medium we observed an
overall enhanced lipid droplet biogenesis in all bro11 strains as
compared to the respective wild-type strains, the increase was
persistent and especially more dense droplets were seen with
bro11 cells expressing αAβ42G37C or αAβ42wt (Figure 6A). This
observation confirms previously reported data on an increased
lipid droplet load in an Aβ42 wild-type strain (Chen et al., 2017).
The perturbation of lipid homeostasis has also been linked
to defects in the ER and mitochondria (Vevea et al., 2015), and
the latter incited us to monitor the level of ROS in the bro11
strains. As shown, and comparable to the PI uptake, we found
similar high levels of ROS in all strains tested indicative that this
is a characteristic mainly associated to the deletion of BRO1 itself
(Figure 6B).
DISCUSSION
During the past decades, several studies validated the use of
yeast to decipher the pathobiology underlying a variety of human
disorders. Especially for degenerative protein folding diseases,
like Huntington’s, Parkinson’s, or Alzheimer’s disease, this led to
the discovery of processes and molecular pathways contributing
to cell demise (Winderickx et al., 2008; Franssens et al., 2010;
Swinnen et al., 2011; Porzoor and Macreadie, 2013; Tenreiro
et al., 2013, 2017; Chen and Petranovic, 2016; Jiang et al., 2016;
Verduyckt et al., 2016; Fruhmann et al., 2017). The insight
gained from these studies were not only relevant in the context
of disease, but they also clarified fundamental aspects on how
a cell manages to maintain proteostasis and the consequences
in case this system fails. In this paper, we used a previously
reported model to study the repercussions when the APP-derived
peptide Aβ42 is expressed in yeast (D’Angelo et al., 2013; Vignaud
et al., 2013). Though this model makes use of a GFP fusion, the
use of the super-toxic Aβ42G37C and the non-toxic Aβ42L34T
mutants clearly demonstrated that the properties of the GFP
fusion are dictated by the Aβ42 peptide moiety. Furthermore, by
comparing constructs with or without an N-terminal fusion with
the α-prepro sequence and conditions that retain the α-prepro
in the ER, it became obvious that the processing in the ER/Golgi
system and the subsequent shuttling into the secretory pathway
is essential to unleash the full toxic capacity of the Aβ42-linker-
GFP fusion. Our data also contradict the argument that the αAβ42
instigated toxicity would simply be due to an overload of the
ER/Golgi processing system because both wild-type and mutant
αAβ42 are processed in the same manner (D’Angelo et al., 2013;
Vignaud et al., 2013) and no toxicity is seen in case of expression
of mutant αAβ42L34T.
The use of our yeast model allowed us to confirm some
data previously reported. This included the impact of αAβ42
on endocytosis (Treusch et al., 2011; D’Angelo et al., 2013),
where we now show that strains with a deletion of SAC6
or RVS167 display an increased αAβ42 toxicity, as well as
the impact on mitochondrial functioning (D’Angelo et al.,
2013; Chen and Petranovic, 2015; Chen et al., 2017), which
we illustrated by co-localization studies and the observation
that αAβ42 enhances ROS formation. These data are relevant
because, indeed, changes in endocytic capacity and mitochondrial
dysfunction are typically seen in the pathogenesis of AD and
have been observed in other AD models as well (Thomas et al.,
2011; Wang et al., 2011; Avetisyan et al., 2016; Schreij et al., 2016;
Dixit et al., 2017; Shoshan-Barmatz et al., 2018; Xu et al., 2018).
However, the observed partial co-localization of toxic αAβ42
with mitochondria may either indicate a direct interaction of
the peptide with this organelle or it may simply be a reflection
of the interaction between the ER and mitochondria through
the membrane contact sites known as ERMES (Kornmann
et al., 2009). This aspect needs to be analyzed in more detail.
Interestingly, mitochondria associated membranes (MAMs), the
mammalian counterpart of ERMES, have already been implicated
in AD (Area-Gomez and Schon, 2016; Paillusson et al., 2016).
Closely related to the observed mitochondrial dysfunction is
our observation that deletion of AIF1, encoding a cell death
effector, has a protective effect on the αAβ42 expressing yeast
cells. This suggests that αAβ42 may induce an apoptotic-like
program in yeast, which fits the finding that neuronal cells
die through apoptosis in AD (Ohyagi et al., 2005; Shoshan-
Barmatz et al., 2018). Our data also show that particularly
the expression of the toxic αAβ42 isoforms is linked to the
formation of ER-associated foci and filamentous structures.
Though we did not study these structures in detail and previously
believed these to represent vesicles (D’Angelo et al., 2013), it
is well-possible that they may in fact be ER aggregates or
clustering of ER membranes, which are both indicative for ER
stress (Varadarajan et al., 2012, 2013; Vevea et al., 2015). Also
ER stress is associated to AD (Gerakis and Hetz, 2018) and
several links between ER stress and mitochondrial dysfunction
have been proposed in this neurodegenerative disorder (Costa
et al., 2012; Barbero-Camps et al., 2014; Erpapazoglou et al.,
2017).
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FIGURE 6 | αAβ42 instigated lipid droplet biogenesis. (A) Nile Red stainings (top panel), a marker for lipid droplets, of wild-type and the bro11 cells expressing
αAβ42wt, αAβ42G37C, or αAβ42L34T or αGFP after 2, 4, or 6 h growth on galactose-containing medium. The bottom panel (yellow) shows magnifications and
deconvolved parts of the top-panel pictures at time point of 6 h. Note that due to deconvolution the picture intensities are enhanced. Scale bars represent 2 µm.
(B) DHE staining of cells deleted for BRO1 transformed with constructs allowing for expression of αAβ42wt, αAβ42L34T, αAβ42G37C, or αGFP after 4 or 24 h growth
on galactose-containing medium. Error bars represent standard deviations of at least four independent transformants.
One of the most striking observations made in our studies is
the role of ESCRT in modulating the αAβ42 toxicity. The ESCRT
system functions in the MVB pathway and several studies have
linked this role of ESCRT to AD. Neurons of AD transgenic
mice were shown to display enlarged MVBs as compared to
the neurons of wild-type mice, and ESCRT was demonstrated
to modulate intracellular Aβ42 accumulation by directing APP
to lysosomal degradation and by enhancing Aβ42 secretion.
In addition, ESCRT components were found associated with
amyloid plaques in transgenic mice and to granular structures
hippocampal neurons of AD diseased human brain (Yamazaki
et al., 2010; Edgar et al., 2015; Willen et al., 2017). However,
apart from its function in the MVB pathway, ESCRT is also
required for the repair of membrane lesions. Here, both cryo-
EM and PI-staining give a strong impression of the presence
of such lesions at the plasma membrane of cells lacking the
ESCRT component Bro1, probably explaining in part the sick
phenotype of the bro11 mutant. As such, our data strongly
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suggest that the role of ESCRT for plasma membrane repair,
which so far was only demonstrated in mammalian cells, is
evolutionary well-conserved. Interestingly, we found that the
disruption of the plasma membrane integrity in the bro11
strain is dramatically exacerbated upon expression of αAβ42 and
that this came along with the deterioration of the ER and an
almost lethal phenotype. This is intriguing for several reasons.
It demonstrates that when the fully processed Aβ42-linker-GFP
arrives at the plasma membrane, the peptide further aggravates
plasma membrane disruption, which given the observed effect
on the ER, might well be involving fusion of secretory vesicles
that contain disordered membranes. The fact that our screens
retrieved the KO strain lacking SSO2 as suppressor of αAβ42
toxicity favors the last possibility. Indeed, SSO2 encodes a plasma
membrane t-SNARE that is required for fusion secretory vesicles
(Grote et al., 2000). Moreover, the data recapitulate observations
made for AD where, as mentioned, Aβ42 was shown to introduce
membrane lesions via different non-excluding mechanisms,
including membrane lipid interaction, alterations in membrane
fluidity, pore formation, or lipid oxidation (Eckert et al., 2000;
Muller et al., 2001; Ambroggio et al., 2005; Rauk, 2008; Axelsen
et al., 2011; Viola and Klein, 2015).
Given the effect of Aβ42 on plasma membrane integrity, the
presence of this peptide also impacts on the overall cellular lipid
homeostasis. In fact, extensive lipid alterations are implicated in
the AD disease pathology but it is still a matter of debate whether
such alterations are the cause or the consequence of AD (Grosgen
et al., 2010; Xiang et al., 2015; El Gaamouch et al., 2016). In yeast,
the expression of Aβ42 has been linked to a transcriptional upshift
of key regulators of lipid metabolism as well as an enhanced
formation of lipid droplets (Chen et al., 2017). Our screens with
the yeast deletion collection and our Nile Red stainings support
the link between Aβ42 and lipid metabolism. Intriguingly, a
recent study demonstrated lipid droplet formation to be an
adaptive response to an acute lipid imbalance in yeast cells.
The same study then also showed that the biogenesis of these
droplets occurs at ER aggregates (Vevea et al., 2015), which we
believe to correspond to the ER-associated foci and filamentous
structures seen when yeast cells express toxic forms of αAβ42,
as mentioned. Notably, also in transgenic mouse models of AD
an enhanced lipid droplet formation is observed (Hamilton et al.,
2010; Yang et al., 2014), again underscoring the relevance of the
data obtained in yeast.
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